Compare
The details that actually shape the buying decision.
Evidence, risk, regulatory flags, cost, and vendor coverage — side by side, without affiliate spin.
01· Subject
Larazotide
Investigational oral peptide for gut-barrier integrity studied mainly in celiac disease.
Tier Blow risk
02· Subject
Thymosin Beta-4
Actin-sequestering peptide with clinical data in ophthalmic wound healing and preclinical tissue repair.
Tier B-Cmed-high risk
01 · At a glance
| Decision factor | Larazotide | Thymosin Beta-4 | Thymosin Alpha-1 |
|---|---|---|---|
| Primary fit | immune support research where you want a clear starting point | tissue repair & recovery and immune support comparisons | longevity & anti-aging and immune support comparisons |
| Evidence | Tier B | Tier B-C | Tier B |
| Risk | low | med-high | medium |
| Experience level | intermediate | intermediate | intermediate |
| Budget tier | premium | mid | mid |
| Administration route | oral | topical, subcutaneous | subcutaneous |
02 · Use case & timing
| Decision factor | Larazotide | Thymosin Beta-4 | Thymosin Alpha-1 |
|---|---|---|---|
| Goal fit | Immune Support | Tissue Repair & Recovery, Immune Support | Longevity & Anti-Aging, Immune Support |
| What users compare it for | Potential reduction in gluten-triggered gut-barrier disruption and GI symptom burden in celiac-focused trial settings. | Ophthalmic: improved corneal epithelial healing. Systemic: wound healing signals in preclinical models. | Immune modulation; clinical literature broader than most RUO peptides. |
| Onset timeline | Barrier effects are expected quickly at the gut interface; symptom outcomes in studies are measured over days to weeks. | Corneal healing studies: days to weeks; systemic repair claims are less well-timed. | Immune biomarkers and clinical outcomes over weeks to months. |
| Main tradeoff | Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter. | Evidence and product availability can still be uneven, so documentation matters more than hype. | Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter. |
03 · Safety & restrictions
| Decision factor | Larazotide | Thymosin Beta-4 | Thymosin Alpha-1 |
|---|---|---|---|
| Adverse effects | Clinical trials report good tolerability with adverse-event rates close to placebo. | Human ophthalmic safety reported as acceptable in trials; systemic safety requires caution. | Generally tolerable in clinical contexts; clinician oversight required. |
| Contraindications | No clear formal contraindications identified, but evidence is limited outside celiac-disease research populations. | Limited formal contraindication data. | Potential interactions with immunotherapies/vaccines. |
| Interaction notes | Minimal systemic absorption means drug-drug interaction risk appears low. | Limited formal interaction studies; treat as unknown outside studied settings. | Potential interactions with immunotherapies/vaccines; do not provide combination advice. |
| Regulatory status | Investigational | Investigational | Investigational |
| FDA flag | No current flag noted | FDA compounding caution | FDA status unclear |
| WADA status | Not listed | WADA S2 | Not listed |
04 · Age & monitoring
| Decision factor | Larazotide | Thymosin Beta-4 | Thymosin Alpha-1 |
|---|---|---|---|
| Supported age ranges | No age guidance yet | No age guidance yet | 35-44, 45-54, 55-64, 65+ |
| Life-stage note | Not yet documented | Not yet documented | Age fit improves later in life because immune-support logic becomes more relevant as immunosenescence rises. |
| Monitoring burden | Not specified | Not specified | medium |
| Follow-up cadence | Not yet documented | Not yet documented | Periodic reassessment every few months, especially if health context is complex. |
05 · Cost & sourcing
| Decision factor | Larazotide | Thymosin Beta-4 | Thymosin Alpha-1 |
|---|---|---|---|
| Typical cycle cost | No reliable estimate yet | $192.00 | $79.98 |
| Estimated monthly cost | No reliable estimate yet | $96.00 | $53.32 |
| Cost confidence | No estimate | High confidence | High confidence |
06 · Before you buy
| Decision factor | Larazotide | Thymosin Beta-4 | Thymosin Alpha-1 |
|---|---|---|---|
| Tracked vendor listings | 0 listings | 1 listing | 1 listing |
| Sourcing note | No tracked product page yet, so sourcing takes more manual review. | Product format varies by listing, so double-check route, concentration, and presentation. | Tracked product pages are available, which makes it easier to review the listing before you click out. |
| Stack-friendly? | Usually stack-friendly | Usually stack-friendly | Usually stack-friendly |
Still deciding
Get a plan tailored to you.
Side-by-side narrows the field. The quiz factors in your goal, experience, and risk tolerance to surface a starting compound and dosing range.